Treatment methods using triaryl methane compounds
AssigneeIcagen, Inc.
InventorsNeil Castle, Gregory Rigdon, Douglas Krafte
Life of this patent
Estimating the term…
Abstract
The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.
Claims15
A method for treating or preventing an inflammatory process, said method comprising administering to a subject suffering from said inflammatory process a therapeutically effective amount of a compound according to Formula I:
- wherein,
- m, n and p are independently selected from 0 and 1 and at least one of m, n and p is 1;
- when m, n and p are all 1, the fluoro substituents at ring 1 and at ring 2 are located at a position independently selected from ortho to the acetamide substituent, meta to the acetamide substituent and para to the acetamide substituent, and the substituent at ring 3 is at a position selected from ortho to the acetamide substituent and para to the acetamide substituent;
- and
- when p is 0, and m is 1 and n is 1, the fluoro substituent at ring 1 is para to the acetamide substituent, and the substituent at ring 2 is located at a position selected from ortho to the acetamide substituent and para to the acetamide substituent.
A method for treating or preventing multiple sclerosis, said method comprising administering to a subject suffering from multiple sclerosis a therapeutically effective amount of a compound according to Formula I:
- wherein,
- m, n and p are independently selected from 0 and 1 and at least one of m, n and p is 1;
- when m, n and p are all 1, the fluoro substituents at ring 1 and at ring 2 are located at a position independently selected from ortho to the acetamide substituent, meta to the acetamide substituent and para to the acetamide substituent, and the substituent at ring 3 is at a position selected from ortho to the acetamide substituent and para to the acetamide substituent;
- and
- when p is 0, and m is 1 and n is 1, the fluoro substituent at ring 1 is para to the acetamide substituent, and the substituent at ring 2 is located at a position selected from ortho to the acetamide substituent and para to the acetamide substituent.
A method for treating or preventing pulmonary hypertension, said method comprising administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a compound according to Formula I:
- wherein,
- m, n and p are independently selected from 0 and 1 and at least one of m, n and p is 1;
- when m, n and p are all 1, the fluoro substituents at ring 1 and at ring 2 are located at a position independently selected from ortho to the acetamide substituent, meta to the acetamide substituent and para to the acetamide substituent, and the substituent at ring 3 is at a position selected from ortho to the acetamide substituent and para to the acetamide substituent;
- and
- when p is 0, and m is 1 and n is 1, the fluoro substituent at ring 1 is para to the acetamide substituent, and the substituent at ring 2 is located at a position selected from ortho to the acetamide substituent and para to the acetamide substituent.
A method for treating or preventing a stroke, said method comprising administering to a subject suffering from a stroke or at risk of having a stroke a therapeutically effective amount of a compound according to Formula I:
- wherein,
- m, n and p are independently selected from 0 and 1 and at least one of m, n and p is 1;
- when m, n and p are all 1, the fluoro substituents at ring 1 and at ring 2 are located at a position independently selected from ortho to the acetamide substituent, meta to the acetamide substituent and para to the acetamide substituent, and the substituent at ring 3 is at a position selected from ortho to the acetamide substituent and para to the acetamide substituent;
- and
- when p is 0, and m is 1 and n is 1, the fluoro substituent at ring 1 is para to the acetamide substituent, and the substituent at ring 2 is located at a position selected from ortho to the acetamide substituent and para to the acetamide substituent.
Dependencies are inferred from the claim text.